anti-Nipah_292
| anti-Nipah_ID | anti-Nipah_292 |
| anti-Nipah Drug | (5Z)-3-ethyl-5-{[5-(2-hydroxyphenyl)furan-2-yl]methylidene}-2-sulfanylidene-1,3-thiazolidin-4-one |
| Nipah virus strain | NiV (NiV-pVSV) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | Vero |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | NA NA |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Pre Infection |
| Duration of Drug delivery for anti-Nipah activity | NA |
| Drug concentration used to test anti-Nipah activity | 2.35 μM |
| Assays used to test anti-Nipah activity | Plaque assay |
| anti-Nipah activity | Decrease [Inhibitory concentration (50 %)] |
| References | Benhur Lee, Michael E. Jung, Michael C. Wolf, Tinghu Zhang Novel antiviral agents for enveloped viruses WO2010044924A |
| Comments | The study documented a series of arylmethylidene rhodanine derivatives having broad- spectrum antiviral activity against enveloped viruses, including but not limited to f_loviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, influenza A, and HIV- 1. The compounds act via a novel mechanism to disrupt viral membranes and inhibit viral attachment, fusion, and/or entry into host cells. |